New Heart Drug From Novartis: Will It Raise The Risk of Alzheimer’s Disease?

LCZ696 is a heart failure drug from Novartis that many observers think will gain FDA approval later this year and go on to become a blockbuster. Perhaps the biggest obstacle to the drug’s success is the fear that it might raise the risk of Alzheimer’s disease. Now a new article in a top cardiology journal lays out the detailed basis for this concern. The authors do not contend that the Alzheimer’s issue will likely ruin the drug’s chances, but they do maintain that the problem needs to be carefully monitored.

I spoke with Milton Packer, the co-principal investigator of PARADIGM-HF, the mega trial that set off the mega excitement about the drug last year. He offers several persuasive arguments that Alzheimer’s disease won’t be the Achilles’ heel of LCZ696.

But first let’s look at the paper…

Click here to read the full post on Forbes.

 

Leave a Reply

%d bloggers like this: